A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication by Huelsmann, Peter M et al.
RESEARCH ARTICLE Open Access
A suicide gene approach using the human pro-
apoptotic protein tBid inhibits HIV-1 replication
Peter M Huelsmann
1†, Andreas D Hofmann
1†, Stefanie A Knoepfel
1, Jasmin Popp
2, Pia Rauch
1,
Francesca Di Giallonardo
3, Christina Danke
2, Eva Gueckel
4, Axel Schambach
5, Horst Wolff
6, Karin J Metzner
1,3*,
Christian Berens
2*
Abstract
Background: Regulated expression of suicide genes is a powerful tool to eliminate specific subsets of cells and
will find widespread usage in both basic and applied science. A promising example is the specific elimination of
human immunodeficiency virus type 1 (HIV-1) infected cells by LTR-driven suicide genes. The success of this
approach, however, depends on a fast and effective suicide gene, which is expressed exclusively in HIV-1 infected
cells. These preconditions have not yet been completely fulfilled and, thus, success of suicide approaches has been
limited so far. We tested truncated Bid (tBid), a human pro-apoptotic protein that induces apoptosis very rapidly
and efficiently, as suicide gene for gene therapy against HIV-1 infection.
Results: When tBid was introduced into the HIV-1 LTR-based, Tat- and Rev-dependent transgene expression vector
pLRed(INS)2R, very efficient induction of apoptosis was observed within 24 hours, but only in the presence of both
HIV-1 regulatory proteins Tat and Rev. Induction of apoptosis was not observed in their absence. Cells containing
this vector rapidly died when transfected with plasmids containing full-length viral genomic DNA, completely
eliminating the chance for HIV-1 replication. Viral replication was also strongly reduced when cells were infected
with HIV-1 particles.
Conclusions: This suicide vector has the potential to establish a safe and effective gene therapy approach to
exclusively eliminate HIV-1 infected cells before infectious virus particles are released.
Background
Both basic and clinical science can greatly benefit from
vectors that induce cell death in a temporally and spatially
controlled manner. Inducible death vectors do not only
contribute to determining the precise effect of specific
cells on behavior [1], development [2], and disease [3,4],
they can also provide critical tools for treatment of many
diverse diseases, including adoptive immune transfer, can-
cer therapy, atherosclerosis, stem cell transplantation, or
viral infection [5-10]. Enzymes and toxins of bacterial or
viral origin are frequently used to kill the targeted cells.
However, they are not necessarily the best choice for all
applications, due to complications that can arise from
immune responses [11], cell cycle dependence [12], and
bystander killing [13]. Ectopic expression of endogenous
pro-apoptotic proteins is an attractive alternative, because
they should be non-immunogenic, they initiate a well-
established cellular program [14,15], and their target cells
are frequently primed for apoptosis [16,17].
The pro-apoptotic proteins most often used in such
applications are caspases [7,8,18,19] and members of the
Bcl-2 family, like BimS [20], Bax [21,22], or truncated Bid
(tBid; BH3 interacting domain death agonist) [23-25].
tBid is generated by cleavage of Bid through activated
caspases-2 and -8, granzyme B, and cathepsins. Translo-
cation of tBid to the mitochondria leads to the release of
cytochrome c resulting in the activation of apoptosis-
inducing caspases [26-28]. Transient or inducible expres-
sion of tBid leads to rapid and efficient induction of
apoptosis in a variety of cell lines [23-25].
Thus, this pro-apoptotic protein represents a promis-
ing candidate for a suicide gene therapy that aims at
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nodeficiency virus type 1 (HIV-1) before infectious
viruses are produced. An infection with HIV-1 is still
incurable despite constant improvements to antiretro-
viral therapy which dramatically reduced the mortality
rate of HIV-1-infected patients [29]. Unfortunately, a
substantial fraction of these patients still experiences
therapy failure and/or serious side effects due to the
treatment. This is often accompanied by the emergence
of drug-resistant viruses [30]. Thus, improving the exist-
ing approaches and finding new antiretroviral strategies
remains a major challenge in the fight against HIV-1.
Numerous suicide genes have already been tested, for
instance, Bax [21], protein kinase R [31], caspase-3 [18],
the host shut-off protein of herpes simplex virus [32],
diphtheria toxin A [33,34], and barnase [35]. However,
most of them were either not efficient enough and/or
cell death was not induced fast enough ultimately result-
ing in insufficient inhibition of HIV-1 replication. The
kinetics observed and the very low protein concentra-
tions needed to induce cell death by tBid [23] would ful-
fill two major requirements of a successful suicide gene:
Efficiency and immediacy.
Another obstacle to this approach is the basal activity
of the HIV-1 LTR promoters used, which led to unspe-
cific cell death of HIV-1 uninfected cells [34,36,37]. The
new retroviral vector pLRed(INS)2R utilizes three dis-
tinct elements originating from HIV-1 to more strin-
gently regulate transgene expression: i) It contains the 5’
and 3’ H I V - 1L T R ,s ot h a te f f i c i e n tg e n ee x p r e s s i o n
requires HIV-1 Tat [38]; ii) the vector comprises the
HIV-1 Rev-responsive element (RRE) leading to Rev-
dependence for mRNA transport from the nucleus to
the cytoplasm [39]; and iii) two HIV-1 inhibitory
sequences (INS) of the gag gene are incorporated into
this vector further enhancing the dependency on Rev in
terms of mRNA export significantly [40]. This vector
fulfills the criterion of HIV-1 specificity and, conse-
quently, provides a safe gene therapy vector.
Here, we replaced the reporter gene dsRed in the
improved HIV-1 indicator plasmid pLRed(INS)2R [40]
with the very potent suicide protein tBid. The resulting
suicide vector was highly dependent on HIV-1 Tat and
Rev for target gene expression. It very efficiently and
rapidly induced apoptosis in vitro before infectious
viruses were released from the HIV-1 infected cell and,
therefore, provides a promising gene therapy approach
against HIV-1 infection.
Results
tBid induces efficiently and rapidly cell death in HeLa SS6
cells
To estimate the susceptibility of the cell line HeLa SS6
towards induction of cell death by the human pro-
apoptotic protein tBid, we transiently co-transfected
these cells with the plasmid pCMV-tBid which constitu-
tively expresses tBid under control of a CMV-promoter,
and with pEGFP-C1 allowing us to determine transfec-
tion efficiencies by measuring green fluorescence. 24
hours after transfection, GFP was expressed in 63% of
the HeLa SS6 cells (Figure 1A). This number increased
to >90% 48 hours after transfection (data not shown).
tBid induced cell death in ~97% of the HeLa SS6 cells
within 24 hours after transfection with pCMV-tBid and
in ~94% of pCMV-tBid/pEGFP-C1 co-transfected cells
(Figure 1A). Similar results were obtained in two addi-
tional independent experiments. Interestingly, the co-
transfected HeLa SS6 cells died before GFP expression
was detected indicating very rapid induction of cell
death, in agreement with published data for HeLa cells
[23]. Time-course experiments confirmed this observa-
tion: Light microscopic analyses showed apoptotic HeLa
SS6 cells already 10 hours after transfection (data not
shown).
Induction of cell death by tBid in the suicide vector
pLtBid(INS)2R strongly depends on the presence of both
HIV-1 Tat and Rev
First, we characterized the control vector pLRed(INS)2R
(Figure 1B) in transiently transfected HeLa SS6 cells or
in HeLa-Tat cells, constitutively expressing the HIV-1
Tat protein. DsRed was not expressed in the absence of
Tat and Rev or in the presence of only one of both viral
proteins (Figures 1C and 2A). Co-transfection of HeLa
SS6 cells with the plasmids pLRed(INS)2R, pCMV-tat
and -rev led in 6.5% of the cells to a >10-fold induction
of dsRed fluorescence after 24 hours (Figure 2A), this
number further increased to >40% during the next 24
hours (data not shown). In HeLa cells stably expressing
the HIV-1 Tat protein, dsRed fluorescence increased up
to three orders of magnitude in the presence of both
Tat and Rev (Figure 1C) [40]. As already observed in
pEGFP-C1-transfected HeLa SS6 cells, it takes about 48
hours to reach sufficient dsRed expression. Next, we
determined the number of dead cells in HeLa SS6 cells
transfected with the control vector pLRed(INS)2Ra l o n e
or in combination with pCMV-tat and/or -rev. All cells
transfected displayed similar morphology (Figure 2B, top
row of panels), and the number of dead cells determined
by propidium iodide staining was in the range of 2.7-
7.2% and, thus, similar in all transfections (Figure 2C).
We then replaced the reporter gene dsRed with tBid to
generate the suicide vector pLtBid(INS)2R( F i g u r e1 B ) .
HeLa SS6 cells were transfected with this vector and co-
transfected with pCMV-tat and/or -rev. 24 hours after
transfection, light microscopic analysis showed that the
morphology of the transfected cells represented living
cells in all transfections containing the suicide vector
Huelsmann et al. BMC Biotechnology 2011, 11:4
http://www.biomedcentral.com/1472-6750/11/4
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pCMV-tat or -rev. However, co-transfection of both
pCMV-tat and -rev together with the suicide vector
pLtBid(INS)2R rapidly induced microscopic signs of cell
death like cell shrinkage and rounding (Figure 2B, lower
row of panels). Cell death was also quantified by staining
the cells with propidium iodide 24 hours after transfec-
tion. 4.5% of the cells were dead in cell cultures trans-
fected only with the suicide vector pLtBid(INS)2R, a
number similar to the control transfections. Thus, induc-
tion of cell death was not observed in the absence of Tat
and Rev despite using the very sensitive HeLa SS6 cell
line. We also did not observe any increase in cell death
induction 48 or 72 hours after transfection (data not
shown). Expression of Rev alone did not lead to induc-
tion of cell death by tBid. Here, only 5.7% of the cells
stained positive with propidium iodide (Figure 2C). The
presence of Tat moderately induced cell death in the
absence of Rev (13%, Figure 2C). Taken together, these
results show that this vector is not leaky. Only expression
of both HIV-1 regulatory proteins Tat and Rev strongly
induced cell death in co-transfected HeLa SS6 cells.
Here, 86% of the cells were dead 24 hours after transfec-
t i o n( F i g u r e2 C ) .A tt h i ss a m et i m ep o i n t ,o n l y6 . 5 %o f
the cells were dsRed-positive when co-transfected with
the control vector pLRed(INS)2R and pCMV-tat plus -rev
indicating that very low amounts of tBid are sufficient to
induce cell death.
Co-transfection of pLtBid(INS)2R and pNL4-3-Nef-IRES-GFP
leads to rapid induction of cell death before virus
particles are produced
To investigate whether HeLa SS6 cells transfected with
the suicide vector pLtBid(INS)2R undergo cell death
before infectious HIV-1 virions are generated and
released, we co-transfected cells with the suicide vector
pLtBid(INS)2R and the HIV-1 full-length clone pNL4-3/
GFP. The latter construct contains a GFP reporter gene
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Figure 1 Induction of cell death by tBid in HeLa SS6 cells and general architecture of the control vector pLRed(INS)2R and the suicide
vector pLtBid(INS)2R.( A) Hela SS6 cells were transfected with pCMV-tBid and/or pEGFP-C1. 24 hours after transfection, cell death and GFP
expression were determined by FACS analysis. Shown is a representative example of three independent experiments. Percentages of GFP-
positive, PI-positive and GFP + PI-positive cells are given for each quadrant. (B) Schematic representation of pLRed(INS)2R and pLtBid(INS)2R.
p17/p24 INS = INS-containing region from gag; RRE = Rev-responsive element. (C) FACS analysis of dsRed expression from pLRed(INS)2R without
(left) and with Rev (right) in HeLa-Tat cells constitutively expressing Tat. A plasmid, driving GFP expression under the control of the CMV
promoter, was transfected as a transfection/expression control (modified from reference [40]).
Huelsmann et al. BMC Biotechnology 2011, 11:4
http://www.biomedcentral.com/1472-6750/11/4
Page 3 of 11dsRed
B
A
C
c
e
l
l
 
c
o
u
n
t
pCMV-rev -- ++
10
0 10
1 10
2 10
3 10
4
0.07
10
0 10
1 10
2 10
3 10
4
0.09
10
0 10
1 10
2 10
3 10
4
6.5
10
0 10
1 10
2 10
3 10
4
0
250
500
750
1000
0.06
- + - + pCMV-tat
pLRed(INS)2R ++ ++
pCMV-rev -- ++
- + - + pCMV-tat
p
L
R
e
d
(
I
N
S
)
2
R
p
L
t
B
i
d
(
I
N
S
)
2
R
pCMV-rev -- ++ -
+
-
+ pCMV-tat
10
0 10
1 10
2 10
3 10
4
5. 7
(2.7)
10
0 10
1 10
2 10
3 10
4
12.9
(4.4)
10
0 10
1 10
2 10
3 10
4
85.7
(7.2)
10
0 10
1 10
2 10
3 10
4
0
250
500
750
1000
4.5
(3.7)
c
e
l
l
 
c
o
u
n
t
propidium iodide
--
pLtBid(INS)2R ++ ++
Figure 2 Induction of cell death by tBid expressed by the suicide vector pLtBid(INS)2R and its dependency on the presence of HIV-1
Tat and Rev. Shown are representative examples of three independent experiments. (A) HeLa SS6 cells were transfected with the control vector
pLRed(INS)2R alone or in addition with pCMV-rev and/or pCMV-tat. 24 hours after infection, expression of dsRed was measured by FACS analysis.
Percentages of dsRed-positive cells are given. (B/C) HeLa SS6 cells were transfected with pLRed(INS)2R or the suicide vector pLtBid(INS)2R alone
or in addition with pCMV-rev and/or pCMV-tat. 24 hours after infection, cell death was determined by light microscopy (B) and PI-staining
followed by FACS analysis (C). Percentages of dead cells are given for cells transfected with pLtBid(INS)2R and in parenthesis for cells tranfected
with pLRed(INS)2R. Data obtained by transfection with the control vector pLRed(INS)2R are depicted in white, the results of transfections with the
suicide vector pLtBid(INS)2R are shown in grey.
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Page 4 of 11within the open reading frame for Nef, ensuring that
GFP is expressed together with Tat and Rev early in the
HIV-1 life cycle. 27 ± 3.3% of the HeLa SS6 cells co-
transfected with pNL4-3/GFP and the control vector
pLRed(INS)2R expressed GFP 24 hours after transfection
in three independent experiments. These transfection
efficiencies are similar to control experiments performed
with a GFP-expressing plasmid of approximately the
same size as pNL4-3/GFP (~15 kb) (data not shown). In
contrast, only 1.0 ± 0.3% of the HeLa SS6 cells co-trans-
fected with pNL4-3/GFP and the suicide vector pLtBid
(INS)2R expressed GFP 24 hours after transfection sug-
gesting that cell death is induced in the co-transfected
HeLa SS6 cells before green fluorescence becomes
detectable. The approximately 28-fold difference in the
amount of GFP-positive cells between both transfections
is highly significant with a p-value <0.001 (Figure 3A).
Transfections using only pNL4-3/GFP revealed similar
results as co-transfections with the control vector pLRed
(INS)2R and pNL4-3/GFP (Figure 3A). We also collected
cell-free supernatant daily for 4 days after transfection
and analyzed the production of virus particles by deter-
mining the content of viral p24 in the supernatant. In
t h ep r e s e n c eo ft h ec o n t r o lv e c t o rp L R e d ( I N S ) 2R, the
replication kinetics of HIV-1 NL4-3 were similar to
those observed in HeLa SS6 cells only transfected with
pNL4-3/GFP (Figure 3B). However, we were not able to
detect p24 in any supernatant from a cell culture co-
transfected with the suicide vector pLtBid(INS)2Ra n d
pNL4-3/GFP within fours days after co-transfection
agreeing with the results obtained by measuring GFP
expression in those cells.
To determine if the inhibition of virus replication is
due to the rapid induction of cell death, we measured
the percentage of dead cells 24 hours after transfection
with pNL4-3/GFP or co-transfections with pNL4-3/GFP
and either the control vector pLRed(INS)2Ro rt h es u i -
cide vector pLtBid(INS)2R. Cells were stained with the
dead cell discrimination reagent. On average, 8.1 ± 1.2%
and 11 ± 1.5% of the cells transfected with pNL4-3/GFP
or co-transfected with pNL4-3/GFP and the control
vector pLRed(INS)2R, respectively, were dead 24 hours
after transfection (Figure 3C). A strongly significant
increase in the percentage of dead cells was observed in
HeLa SS6 cells 24 hours after co-transfection with
pNL4-3/GFP and the suicide vector pLtBid(INS)2R
(average: 45 ± 4.5%, p < 0.001, Figure 3C). This clearly
demonstrates that the expression of Tat and Rev from
transfected HIV-1 DNA induces cell death rapidly and
efficiently enough to prevent the production of new
virus particles.
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Figure 3 Co-transfection of pLtBid(INS)2Ra n dp N L 4 - 3 / G F P
leads to rapid induction of cell death before infectious viruses
are produced. Data represent the means and standard deviations
of three independent experiments. p-values <0.001 indicate the
highly significant impact of tBid on the inhibition of virus
production and the induction of cell death. (A) HeLa SS6 cells were
transfected with pNL4-3/GFP alone or co-transfected with pNL4-3/
GFP and either pLRed(INS)2R or pLtBid(INS)2R. 24 hours after
transfection, viral gene expression was determined by analyzing GFP
expression using FACS. (B) HeLa SS6 cells were transfected with
pLRed(INS)2R (open triangles) or pLtBid(INS)2R (black circles)
together with pNL4-3/GFP or transfected with pNL4-3/GFP alone
(open circles). Release of viral particles was monitored daily for 4
days by p24 antigen ELISA. (C) Determination of cell death in HeLa
SS6 cells transfected only with pNL4-3/GFP or co-transfected with
pLRed(INS)2R and pNL4-3/GFP or with pLtBid(INS)2R and pNL4-3/
GFP, 24 hours after transfection. Percentages of DCD-stained cells
are depicted.
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Page 5 of 11Inhibition of HIV-1 NL4-3 replication in pLtBid(INS)2R-CD4
transfected HeLa SS6 cells
Next, we investigated the functionality of our suicide vec-
tor pLtBid(INS)2R in the context of infectious HIV-1 par-
ticles. We introduced a CMV-expressed cDNA for the
HIV-1 receptor CD4 into the suicide vector pLtBid(INS)
2R obtaining pLtBid(INS)2R-CD4. We transfected HeLa
SS6 cells, which do not physiologically express the CD4
receptor with pLtBid(INS)2R-CD4. This guarantees that
only cells containing the suicide vector would be permis-
sive for HIV-1 infection, thereby eliminating the possibi-
lity of virus replication in HeLa SS6 cells only transfected
with a CD4 expression plasmid if a co-transfection
approach using separate plasmids would have been used.
pLRed(INS)2R-CD4 was constructed as control vector.
HeLa SS6 cells were infected with HIV-1 NL4-3 36 hours
after transfection and viralp 2 4w a sm e a s u r e dd a i l yi n
cell-free supernatants. To control for transfection effi-
ciency and consistency, CD4 expression was measured 24
hours after infection by FACS analysis. pLRed(INS)2R-
CD4- and pLtBid(INS)2R-CD4 transfected HeLa SS6 cells
expressed similar levels of CD4 (Figure 4A). HIV-1 NL4-
3 did not replicate in mock-transfected or untransfected
HeLa SS6 cells (Figure 4B; data not shown). HIV-1 NL4-
3 replication was inhibited by 75 ± 6.1% on day 3 and 69
± 6.4% on day 4 after infection compared to virus replica-
tion in HeLa SS6 cells transfected with the control vector
pLRed(INS)2R-CD4 (Figure 4B,C). We also quantified the
amount of dead cells 48 hours after infection, i.e.,
84 hours after transfection. 28 ± 0.5% of the mock-
transfected and 33 ± 1.3% of the pLRed(INS)2R-CD4
transfected HeLa SS6 cells were dead (Figure 4D). These
percentages of dead cells are higher compared to the
amount of dead cells in our previous HeLa SS6 transfec-
tions using pLRed(INS)2R and pNL4-3/GFP. This is
mainly due to the different time points chosen to mea-
sure the proportion of dead cells (24 versus 84 hours
after transfection). An even higher increase in the num-
ber of dead cells was observed in pLtBid(INS)2R-CD4
transfected HeLa SS6 (46 ± 5.0%, Figure 4D) suggesting
that those cells were also dying due to the induction of
tBid expression by HIV-1 NL4-3. This high amount of
dead cells was significantly different compared to mock-
transfected cells (p = 0.04); the difference was not signifi-
cant compared to pLRed(INS)2R-CD4-transfected HeLa
SS6 cells (p = 0.08, Figure 4D). However, the latter is
caused by cytopathic effects resulting from the HIV-1
infection itself, which would also explain the higher
amount of dead cells in pLRed(INS)2R-CD4 transfected
HeLa SS6 cells compared to mock-transfected cells.
Discussion
Despite several set-backs, the development of suicide
vector systems can still be a promising approach for
gene therapy of HIV-1 infection [5,41]. They can be
used to reduce viral burden by killing infected, virus-
producing cells [9,21] and to target and eliminate the
reservoir of latent HIV-1 [5]. They might even be used
to modify stem cells prior to their transplantation into
the patient [42,43]. These booby-trapped hematopoietic
cells would commit suicide upon infection by HIV-1,
thereby interrupting the viral replicative cycle and redu-
cing viral load. However, for such an approach to func-
tion, several requirements have to be fulfilled. First, the
suicide vector must be strongly HIV-1 dependent with-
out compromising the rapid induction of the suicide
gene by the viral proteins. Second, the suicide gene itself
has to be fast and efficient in its induction of cell death,
to ensure target cell elimination before infectious virus
particles are generated. Third, the suicide gene should
not be immunogenic. Fourth, the suicide system has to
be delivered efficiently to the HIV-1 target cells. So far,
no published system fulfills all of these necessities. In
our proof-of-concept study, we addressed the first three
requirements.
The suicide vector pLtBid(INS)2Rc o n t a i n st h eH I V - 1
LTRs, thus, expression of tBid depends on HIV-1 Tat.
However, the HIV-1 LTR alone would lead to unspecific
expression of tBid as frequently observed using solely
HIV-1 LTR-based vector systems [21,32,44]. The RRE
present in the suicide vector pLtBid(INS)2R reduces this
leakiness, because expression now depends on both Tat
and Rev [9,33,34,45]. In addition, the suicide vector
pLtBid(INS)2R comprises two INS-containing regions of
the HIV-1 gag gene. They increase the dependency on
Rev, thereby reducing basal activity even further
[40,46,47]. We tested the control vector pLRed(INS)2Ri n
HeLa SS6 cells showing that the expression of dsRed is
strongly dependent on the simultaneous presence of Tat
and Rev. We observed no leakiness of the suicide vector
pLtBid(INS)2R in the very sensitive cell line HeLa SS6
transfected only with pLtBid(INS)2Ro rc o - t r a n s f e c t e d
with pCMV-rev. The presence of Tat alone slightly
induced the expression of tBid followed by induction of
cell death in a small number of cells. However, only the
presence of both Tat and Rev significantly enhanced the
induction of cell death introduced by tBid showing that
the system is not leaky and that it strongly depends on
the HIV-1 proteins Tat and Rev. It is promising that no
leakiness was observed in cells stably transfected with the
control vector pLRed(INS)2R for more than 3 months. In
addition, dsRed expression was still inducible by HIV-1
Tat and Rev after 3 months [48].
The human pro-apoptotic protein tBid is the effector
molecule of our suicide vector pLtBid(INS)2R. tBid ful-
fills several qualifications of a suitable suicide protein: i)
cell death is induced within hours after expression of
tBid, ii) tBid is efficient in very low concentrations [23],
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Page 6 of 11iii) it is not immunogenic as, for instance, viral suicide
proteins [11,32], and iv) it has been successfully applied
as suicide protein in a gene therapeutic approach where
breast cancer cells were specifically killed by tBid in
vitro [24]. We observed rapid induction of cell death in
HeLa SS6 cells within 24 hours after transfection of
pCMV-tBid. Similar kinetics and efficacies had pre-
viously been shown in several cell lines [23,25,49]
including Jurkat T lymphocytes [50].
We tested the cell death inducing properties of our
suicide vector pLtBid(INS)2Rw i t hr e s p e c tt oH I V - 1
using different experimental approaches. First, we co-
transfected cells with the suicide vector pLtBid(INS)2R
and the full-length HIV-1 clone pNL4-3/GFP. A few
hours after transfection, before infectious HIV-1 parti-
cles were generated, the cells started to die. Here, no
release of virus particles was observed as revealed by
p24 ELISA. Second, cells were transfected with the sui-
cide vector pLtBid(INS)2R-CD4 and infected with infec-
t i o u sH I V - 1N L 4 - 3 .V i r u sr e p l i c a t i o nw a ss t r o n g l y
reduced and the amount of dead cells increased com-
pared to HeLa SS6 cells transfected with the control
vector pLRed(INS)2R-CD4. Although we have not mea-
sured tBid directly in dying cells due to the very low
amounts of tBid sufficient to induce apoptosis [23,49],
which makes it very difficult to detect tBid with conven-
tional detection methods, we are convinced that tBid
expression induced cell death. In all our experiments,
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Figure 4 Inhibition of HIV-1 NL4-3 replication in pLtBid(INS)2R-CD4 transfected HeLa SS6 cells. HeLa SS6 cells were transfected with the
control vector pLRed(INS)2R-CD4 or the suicide vector pLtBid(INS)2R-CD4. 36 hours after transfection, HeLa SS6 cells were infected with HIV-1
NL4-3. The data shown are from two independent experiments, each performed in duplicate. (A) CD4 expression was determined by FACS
analysis 24 hours after infection with HIV-1 NL4-3 in mock transfected (dotted line), pLRed(INS)2R-CD4 transfected (black line), and pLtBid(INS)2R-
CD4 transfected (grey line) HeLa SS6 cells. (B) Release of viral particles was determined by p24-ELISA using cell-free supernatants of HIV-1 NL4-3
infected HeLa SS6 cells transfected with pLRed(INS)2R-CD4 (open triangles), pLtBid(INS)2R-CD4 (black circles), or mock controls (open circles).
Shown is one representative assessment. (C) Depicted is the residual replication of HIV-1 NL4-3 at days 3 and 4 post infection in pLtBid(INS)2R-
CD4 transfected HeLa SS6 cells (black) as measured by p24 antigen ELISA, background subtracted, and normalized to p24 values obtained in
pLRed(INS)2R-CD4 transfected HeLa SS6 cells (white). (D) Determination of cell death in HeLa SS6 cells in mock transfected (grey), pLRed(INS)2R-
CD4 transfected (white), and pLtBid(INS)2R-CD4 transfected (black bar) cells 48 h after infection with HIV-1 NL4-3. Percentages of DCD-stained
cells are depicted.
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Page 7 of 11we used the isogenic vector pLRed(INS)2R as control
and we never observed any indication of increased cell
death induced by dsRed.
In contrast to the co-transfection experiments using
pNL4-3/GFP, the inhibition of virus particle production
was incomplete when pLtBid(INS)2R-CD4 transfected
HeLa SS6 cells were infected with HIV-1 NL4-3. This is
not due to the replacement of nef by gfp in pNL4-3/
GFP, because we obtained similar results using pNL4-3
(data not shown). Several possible reasons could explain
this observation. Residual replication might be due to
the long CD4 half-life of approximately 20-24 hours on
the cell surface [51,52] when rapidly dividing cells lose
the transiently transfected suicide vector pLtBid(INS)2R-
CD4. We have observed that transiently transfected
plasmids were not detectable anymore after a few cell
divisions in HeLa SS6 cells (unpublished observations).
This would lead to the presence of cells which do not
contain the suicide vector pLtBid(INS)2R-CD4, but still
exhibit sufficient amounts of CD4 to promote HIV-1
entry and replication. It is known for a T cell-line
adapted HIV-1 strain like NL4-3 that low CD4 expres-
sion does not impair virus replication [53]. It has also
been described that cells lacking the CCR5 or CXCR4
receptor can be rendered CCR5
+ or CXCR4
+ by uptake
of membrane-derived microparticles from CCR5- or
CXCR4-positive cells [54]. There is evidence that CD4
+
cells undergoing programmed cell death shed micropar-
ticles that carry CD4 [55], offering another possibility of
how co-cultured cells not expressing the CD4 antigen
themselves could become infected after CD4 uptake.
The incomplete replication suppression might also be
caused by differences in the levels and kinetics of HIV-1
Tat and Rev expression in the more physiological condi-
tions using infectious virus particles [56,57]. A critical
threshold level of Rev is required for highly productive
HIV-1 infection [58]. In contrast to the HIV-1 genome,
pLtBid(INS)2R-CD4 contains a duplication of the INS
region. In the absence of Rev, gene expression of gag/
pol and env mRNA is not completely inhibited in the
context of wild-type HIV-1 [59], but this INS duplica-
tion results in enhanced suppression of gene expression.
Thus, it might be that a threshold level of Rev for suffi-
cient expression of tBid was not reached in all cells by
the infection. To address this concern, we are currently
focusing on improving the pro-apoptotic properties of
tBid by (i) introducing mutations that eliminate ubiqui-
tin acceptor sites and thereby improve tBid’s intracellu-
lar stability [60] and by (ii) modifying its N-terminal
sequence to allow myristoylation of tBid, which pro-
motes targeting to mitochondria and enhances pro-
apoptotic activity in cell culture [61]. A similar low effi-
ciency was recently described for replication-competent
wild-type HIV-1 virions compared to single-cycle VSV-
G pseudotyped HIV-1 virus particles in another investi-
gation of a potential Rev-dependent suicide vector [9].
Conclusions
I ns u m m a r y ,w eh a v es h o w ni nt h r e ei n d e p e n d e n t
experimental settings that the induction of cell death by
tBid in the context of our suicide vector pLtBid(INS)2R
is not leaky, occurs very rapidly, and is highly dependent
on HIV-1. Furthermore, the production of virus parti-
cles and virus replication is substantially inhibited in
cells transfected with the suicide vectors pLtBid(INS)
2R/-CD4. Thus, this vector system shows promise as a
gene therapy vector.
Methods
Plasmid constructions
The cDNA of tBid was cloned into pEGFP-C1 (Invitro-
gen, Karlsruhe, Germany) by replacing GFP by tBid,
which was isolated from the plasmid pWHE171 [23] to
obtain the expression plasmid pCMV-tBid. For the con-
struction of the suicide vector, pLRed(INS)2R [40] and
p C M V - t B i dw e r er e s t r i c t e dw i t hN h e Ia n dM s c Io r
EcoRV (New England Biolabs), respectively. tBid was
ligated into the vector replacing dsRed. To obtain the
correct amino acid sequence of tBid, this plasmid was
restricted with NheI and BssHII (NEB) and a linker was
added consisting of the oligonucleotides ptBid-linker1
5’-CGCGCGGGCCGG-3’ and ptBid-linker2 5’-CTAG
CCGGCCCG-3’ (biomers.net, Ulm, Germany). This vec-
tor is referred to as pLtBid(INS)2R.
For including the HIV-1 receptor CD4 in the suicide
vector pLtBid(INS)2R and the control vector pLRed
(INS)2R, the open reading frame of the human CD4
mRNA was amplified from cDNA of HeLa CD4
+ cells,
kindly provided by D. Kabat (Oregon Health & Science
University, Portland), using the oligonucleotides CD4 81
Hind III 5’- CGAATTCAAGCTTCAGAGGCCCTGC-
CATTTCTG-3’ and CD4 1700 rc Xho I 5’- CATA-
GACTCGAGCACTCAACCAGTGAAGCCGG-3’ (bio-
mers.net, restriction sites are underlined). The CD4
amplicon and the expression vector pcDNA3.1 (Invitro-
gen) were restricted with HindIII and XhoI and ligated.
The CMV-promoter-CD4 cassette was subcloned into
the suicide vector pLtBid(INS)2Ra n dt h ec o n t r o lv e c t o r
pLRed(INS)2R by respective restrictions with NotI and
subsequent ligations. These vectors are referred to as
pLtBid(INS)2R-CD4 and pLRed(INS)2R-CD4.
pNL4-3/GFP (contains GFP within the nef ORF) was
kindly provided by F. Kirchhoff (Institute of Virology,
Ulm, Germany), pCMV-tat by B. Ensoli (National
AIDS Center, Rome, Italy), and pCMV-rev is a gift
from J. Hauber (Heinrich-Pette Institute, Hamburg,
Germany). All vector sequences were confirmed by
sequencing.
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Page 8 of 11Cells and transfections
HeLa SS6 cells were maintained in Dulbecco’s modified
Eagle medium (DMEM, Invitrogen) supplemented with
10% heat-inactivated fetal bovine serum (Invitrogen),
170 mM penicillin and 40 mM streptomycin. Cells were
transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Briefly,
cells were plated in 6- or 12-well cell culture plates.
When ≥90% confluence was reached, cells were trans-
fected with plasmids in a total amount of 4-6 μgo r1 . 5 -
3 μg per 6- or 12-well, respectively. Co-transfections
were carried out with equal amounts of each plasmid.
Light- and fluorescence microscopy was performed
using an AxioVert 200 microscope (Zeiss).
FACS analysis of cell death and reporter gene expression
To analyze cell death, propidium iodide (Merck) was
used for all staining of non-infected cells. For safety rea-
sons, cells potentially infected with HIV-1 were stained
with the “dead cell discriminator (DCD) kit” (Miltenyi
Biotec), which includes a cell fixation step according to
the manufacturer’s instructions. CD4 expression was
analyzed by FACS using the murine anti-CD4 antibody
SK3-phycoerythrin (Becton Dickinson). FACS analyses
were performed using a FACSCalibur (Becton Dickin-
son). GFP- and dsRed expression was also determined
by FACS.
Viruses and infections
HIV-1 NL4-3 virus stock was generated and character-
ized as previously described [62]. Cells were infected
36 hours after transfection with pLtBid(INS)2R-CD4 or
pLtBid(INS)2R-CD4 with a multiplicity of infection
(MOI) of 0.01. Two hours after infection, cells were
washed twice with PBS and further cultivated with
fresh medium. Cell-free supernatants of cell cultures
transfected with pNL4-3/GFP or infected with HIV-1
NL4-3 were collected daily after infection and virus
production was estimated by an in-house p24 ELISA
with a detection limit of 0.125 ng/ml as previously
described [63].
Statistical analysis
Differences in the induction of apoptosis, the expression
of the reporter genes dsRed and GFP, or virus replica-
tion were tested for statistical significance by using a
two-tailed Student’s t-test. A p-value of <0.05 was
considered a significant difference between two groups,
a p-value below 0.001 highly significant.
Note
This work was presented in part at the Deutsch-österrei-
chischer AIDS Kongress, 27-30 June 2007, Frankfurt,
Germany (abstract F.24); 14. Jahrestagung der Deutschen
Gesellschaft für Gentherapie, 18-20 July 2007, Heidel-
berg, Germany (abstract); and 3. European Congress of
Virology, 1-5 September 2007, Nuremberg, Germany
(abstract GET006).
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